• SKYRIZI® (risankizumab) has been listed in Ontario (ON) and Alberta (AB) formularies for the treatment of moderately to severely active ulcerative colitis (UC).
  • SKYRIZI® (risankizumab), an IL-23 inhibitor3, received positive reimbursement recommendations for Crohn's disease (CD) and ulcerative colitis (UC).
  • AbbVie received a letter of intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI® for UC in November 2025.

MONTREAL, May 4, 2026 /CNW/ - Today, AbbVie (NYSE:ABBV) has announced two positive updates for Canadians living with UC, including those in Ontario and Alberta.

To date, SKYRIZI® (risankizumab) has been listed for the treatment of UC on the public drug formularies in Quebec (Médicament d'exception), Nova Scotia (Exception Drug Status), Non-Insured Health Benefits (NIHB) (Limited Use), Prince Edward Island (Special Authorization), Alberta (Special Authorization) and Ontario (Exceptional Access Program). We are continuing our efforts to make sure SKYRIZI® (risankizumab) is accessible for patients with UC and listed on the public drug formularies across the country in a timely manner.

Canada's Drug Agency (CDA-AMC) has recommended SKYRIZI® (risankizumab) to be reimbursed with conditions by public drug plans for the treatment of adults with moderately to severely active UC who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor if certain conditions are met last November.